company background image
A304360 logo

S.Biomedics KOSDAQ:A304360 Stock Report

Last Price

₩22.70k

Market Cap

₩266.6b

7D

14.6%

1Y

198.7%

Updated

22 Nov, 2024

Data

Company Financials

S.Biomedics Co., Ltd.

KOSDAQ:A304360 Stock Report

Market Cap: ₩266.6b

A304360 Stock Overview

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. More details

A304360 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

S.Biomedics Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for S.Biomedics
Historical stock prices
Current Share Price₩22,700.00
52 Week High₩51,600.00
52 Week Low₩7,150.00
Beta0
11 Month Change-29.50%
3 Month Change-12.02%
1 Year Change198.68%
33 Year Changen/a
5 Year Changen/a
Change since IPO20.55%

Recent News & Updates

Here's Why S.Biomedics (KOSDAQ:304360) Can Afford Some Debt

Jul 19
Here's Why S.Biomedics (KOSDAQ:304360) Can Afford Some Debt

Recent updates

Here's Why S.Biomedics (KOSDAQ:304360) Can Afford Some Debt

Jul 19
Here's Why S.Biomedics (KOSDAQ:304360) Can Afford Some Debt

Shareholder Returns

A304360KR BiotechsKR Market
7D14.6%-8.1%2.9%
1Y198.7%18.1%-2.8%

Return vs Industry: A304360 exceeded the KR Biotechs industry which returned 21.1% over the past year.

Return vs Market: A304360 exceeded the KR Market which returned -4% over the past year.

Price Volatility

Is A304360's price volatile compared to industry and market?
A304360 volatility
A304360 Average Weekly Movement19.5%
Biotechs Industry Average Movement8.0%
Market Average Movement5.6%
10% most volatile stocks in KR Market11.5%
10% least volatile stocks in KR Market2.7%

Stable Share Price: A304360's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A304360's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
200552n/awww.sbiomedics.com

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson’s disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration; CF-TED-N for the treatment of stroke; and CF-FECS-DF for the treatment of wound. The company provides testing services; and owns platform technologies for developing cell therapy products.

S.Biomedics Co., Ltd. Fundamentals Summary

How do S.Biomedics's earnings and revenue compare to its market cap?
A304360 fundamental statistics
Market cap₩266.63b
Earnings (TTM)-₩9.77b
Revenue (TTM)₩11.90b

22.4x

P/S Ratio

-27.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A304360 income statement (TTM)
Revenue₩11.90b
Cost of Revenue₩5.99b
Gross Profit₩5.91b
Other Expenses₩15.69b
Earnings-₩9.77b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-831.89
Gross Margin49.70%
Net Profit Margin-82.10%
Debt/Equity Ratio120.3%

How did A304360 perform over the long term?

See historical performance and comparison